Skip to main content
placeholder image

Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.

Journal Article


Abstract


  • Anthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.

Publication Date


  • 2001

Citation


  • Ranson, M. R., Cheeseman, S., White, S., & Margison, J. (2001). Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.. Critical reviews in oncology/hematology, 37(2), 115-120. doi:10.1016/s1040-8428(00)00107-4

Web Of Science Accession Number


Start Page


  • 115

End Page


  • 120

Volume


  • 37

Issue


  • 2

Abstract


  • Anthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.

Publication Date


  • 2001

Citation


  • Ranson, M. R., Cheeseman, S., White, S., & Margison, J. (2001). Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.. Critical reviews in oncology/hematology, 37(2), 115-120. doi:10.1016/s1040-8428(00)00107-4

Web Of Science Accession Number


Start Page


  • 115

End Page


  • 120

Volume


  • 37

Issue


  • 2